Rapid Vaccination of Hard-To-Reach Populations
Recruitment status was: Recruiting
The purpose of this study is to develop and determine the effectiveness of a multi-level community participatory intervention designed to rapidly immunize hard-to-reach populations, including substance users, within disadvantaged minority communities.
Specific Aims of the project are as follows:
- To identify the relative contributions of personal factors and structural barriers to immunization status in hard-to-reach populations.
- To estimate the size of the hard-to-reach population in specified disadvantaged urban communities using venue-based sampling, probability-based sampling, capture-recapture methods and modified Delphi techniques.
- To compare vaccination rates in hard-to-reach populations between neighborhoods that receive a community-based vaccine outreach intervention versus neighborhoods where vaccines are offered through standard public health programs, using an incremental crossover multilevel community intervention design.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Rapid Vaccination of Hard-to-Reach Populations|
- Compare vaccination rates in selected neighborhoods before and after a multilevel community-based participatory intervention trial.
- Determine and identify the relative contributions of personal factors and structural barriers to immunization status in hard-to-reach populations.
- Estimate the size of the hard-to-reach populations.
|Study Start Date:||February 2004|
|Estimated Study Completion Date:||October 2005|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00155974
|United States, New York|
|Center for Urban Epidemiologic Studies, The New York Academy of Medicine|
|New York, New York, United States, 10029|
|Principal Investigator:||David Vlahov, PhD||Center for Urban Epidemiologic Studies, The New York Academy of Medicine|
|Principal Investigator:||Sandro Galea, MD, DrPH||Center for Urban Epidemiologic Studies, The New York Academy of Medicine|